NCT07218601

Using E-Nose Technology to Track Treatment Response in People With Non-Small Cell Lung Cancer

Electronic Nose (E-nose) Technology to Assess Pathologic Response and Post- Treatment Progression for Non-small Cell Lung Cancer: a Phase II Study

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Memorial Sloan Kettering Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The researchers are doing this study to test the ability of a new technology called breathprinting, or electronic nose (E-Nose), to measure changes in certain chemicals in the breath before and after standard neoadjuvant therapy in people with NSCLC.

Conditions

• Non-Small Cell Lung Cancer

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	Breath sample collection	Cohort 1: patients undergoing neoadjuvant treatment (stages II to IIIB) will undergo breath sampling (1) at baseline before any treatment, (2) 2 weeks after neoadjuvant therapy, (3) 2 weeks after surgery, (4) 6 months after surgery, and (5) every 6 months for the first 2 years. Cohort 2: patients who are planned to undergo upfront surgery will undergo breath sampling (1) at baseline before upfront surgery, (2) 2 weeks after surgery, (3) 6 months after surgery, and (4) every 6 months for the first 2 years.
DIAGNOSTIC_TEST	Research blood collection	Cohort 1: Blood sample collections will coincide with the breath collection schedule.

Timeline

• Start date: 2025-10-10
• Primary completion: 2027-10-01
• Completion: 2027-10-01
• First posted: 2025-10-20
• Last updated: 2026-03-23

Locations

7 sites across 1 country: United States